Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Ratio (2019 - 2025)

Cyclerion Therapeutics has reported Equity Ratio over the past 7 years, most recently at 0.92 for Q3 2025.

  • Quarterly results put Equity Ratio at 0.92 for Q3 2025, down 0.6% from a year ago — trailing twelve months through Sep 2025 was 0.92 (down 0.6% YoY), and the annual figure for FY2024 was 0.92, up 9.51%.
  • Equity Ratio for Q3 2025 was 0.92 at Cyclerion Therapeutics, roughly flat from 0.91 in the prior quarter.
  • Over the last five years, Equity Ratio for CYCN hit a ceiling of 0.92 in Q4 2024 and a floor of 0.34 in Q1 2023.
  • Median Equity Ratio over the past 5 years was 0.84 (2023), compared with a mean of 0.77.
  • Biggest five-year swings in Equity Ratio: plummeted 56.96% in 2023 and later surged 154.86% in 2024.
  • Cyclerion Therapeutics' Equity Ratio stood at 0.81 in 2021, then decreased by 28.9% to 0.58 in 2022, then surged by 45.99% to 0.84 in 2023, then increased by 9.51% to 0.92 in 2024, then decreased by 0.92% to 0.92 in 2025.
  • The last three reported values for Equity Ratio were 0.92 (Q3 2025), 0.91 (Q2 2025), and 0.89 (Q1 2025) per Business Quant data.